3 Stocks That Could Pick Up Steam: Cardiol Therapeutics (CRDL), Autonomix Medical (AMIX), Regentis Biomaterials (RGNT)

Healthcare stocks continued to attract investor attention as several small-cap biotech and pharmaceutical companies navigated shifting market conditions, ongoing clinical developments, and broader sector volatility. Companies operating within the healthcare space remain focused on strengthening their financial positions, advancing product pipelines, and maintaining operational stability while positioning themselves for potential long-term growth opportunities. Investors are closely monitoring trading performance, capital management strategies, and upcoming milestones as these firms work to enhance shareholder value in an increasingly competitive environment.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) continues to advance its lead cardiovascular therapy at a time when inflammation-focused treatment strategies are receiving growing attention across the biotech sector. As investors evaluate emerging cardiovascular companies, late-stage clinical execution and differentiated science remain important drivers of long-term valuation potential.

Market Momentum

As of May 28, 2026, CRDL closed at $1.28, unchanged for the session, with trading volume of 177,548 shares compared to an average volume of 689,388 shares. The company currently maintains a market capitalization of $147.548M and a beta of 0.43, reflecting relatively moderate volatility for a clinical-stage biotech company. Shares continue trading within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.32 suggests substantial upside potential tied to future clinical and regulatory milestones.

Late-Stage Development Progress

Cardiol’s Phase III MAVERIC trial evaluating CardiolRx™ for recurrent pericarditis remains the company’s primary near-term catalyst. The randomized, double-blind, placebo-controlled study has surpassed 75% patient enrollment and was designed in collaboration with the U.S. Food and Drug Administration following encouraging Phase II discussions.

Clinical Foundation

Earlier clinical findings demonstrated reductions in pericarditis-related pain, inflammation, and recurrence frequency while also showing favorable safety and tolerability outcomes. These results have helped strengthen the clinical rationale supporting CardiolRx™ as a potential treatment option for patients suffering from recurrent inflammatory heart disease.

Outlook

With enrollment continuing to advance and earlier clinical data supporting the therapy’s development profile, Cardiol appears increasingly well-positioned as it moves toward future regulatory discussions and potential commercialization opportunities.

Autonomix Medical Inc (AMIX)

Autonomix Medical Inc (NASDAQ: AMIX) started the day on May 28, 2026, with a price decrease of -0.57% at $0.41. During the day, the stock rose to $0.42 and sank to $0.38. Taking a long-term approach, AMIX posted a 52-week range of $0.20-$2.64.

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 35.84%. Meanwhile, its Annual Earnings per share during the time was 35.84%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 63.62%. This publicly-traded company’s shares outstanding now amount to $11.41 million, simultaneously with a float of $10.88 million. The organization now has a market capitalization of $4.73 million.

Regentis Biomaterials Ltd (RGNT)

As of May 28, 2026, Regentis Biomaterials Ltd (NYSEAMERICAN: RGNT) got off with the flyer as it spiked 1.02% to $1.98. During the day, the stock rose to $2.02 and sank to $1.87. Taking a more long-term approach, RGNT posted a 52-week range of $1.82-$8.35.

In the past 5-year timespan, the Healthcare sector firm’s annual sales growth was -71.58%. Meanwhile, its Annual Earnings per share during the time were -71.58%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 97.19%. This publicly-traded company’s shares outstanding now amount to $4.93 million, simultaneously with a float of $2.48 million. The organization now has a market capitalization of $10.26 million.